Subscribe to RSS
DOI: 10.1055/a-2218-8352
A Difficult Case of Optic Neuropathy: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Ein schwieriger Fall optischer Neuropathie: Myelin-Oligodendrozyten-Glykoprotein-Antikörper-assoziierte Erkrankung (MOGAD)
Background
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently defined inflammatory demyelinating disease, that generally affects the optic nerve (ON) in adults and the central nervous system in children [1], [2]. The specific clinical phenotype, radiological findings, and neurological manifestations enable its distinction from other central nervous system inflammatory demyelinating diseases (CNS IDDs) such as aquaporine-4-IgGQ neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) [3] [4] [5].
Publication History
Received: 27 October 2023
Accepted: 27 November 2023
Article published online:
23 April 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Messias K, Marques VD, Messias A. Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis: an update. Arq Bras Oftalmol 2022; 86: 83-92 DOI: 10.5935/0004-2749.20230012.
- 2 Banwell B, Bennett JL, Marignier R. et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 2023; 22: 268-282 DOI: 10.1016/S1474-4422(22)00431-8.
- 3 Sechi E, Cacciaguerra L, Chen JJ. et al. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Front Neurol 2022; 13: 885218 DOI: 10.3389/fneur.2022.885218.
- 4 Chen JJ, Flanagan EP, Jitprapaikulsan J. et al. Myelin Oligodendrocyte Glycoprotein Antibody–Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. Am J Ophthalmol 2018; 195: 8-15 DOI: 10.1016/j.ajo.2018.07.020.
- 5 Foo R, Yau C, Singhal S. et al. Optic Neuritis in the Era of NMOSD and MOGAD: A Survey of Practice Patterns in Singapore. Asia Pac J Ophthalmol (Phila) 2022; 11: 184-195 DOI: 10.1097/APO.0000000000000513.
- 6 Cobo-Calvo A, Sepúlveda M, Rollot F. et al. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflammation 2019; 16: 134 DOI: 10.1186/s12974-019-1525-1.
- 7 Jarius S, Ruprecht K, Kleiter I. et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016; 13: 280 DOI: 10.1186/s12974-016-0718-0.
- 8 Lopez JA, Houston SD, Tea F. et al. Validation of a Flow Cytometry Live Cell-Based Assay to Detect Myelin Oligodendrocyte Glycoprotein Antibodies for Clinical Diagnostics. J Appl Lab Med 2022; 7: 12-25 DOI: 10.1093/jalm/jfab101.
- 9 Waters PJ, Komorowski L, Woodhall M. et al. A multicenter comparison of MOG-IgG cell-based assays. Neurology 2019; 92: e1250-e1255 DOI: 10.1212/WNL.0000000000007096.